In the publication "Biomarkers of response to Ocrelizumab in relapse -remitting Multiple Sclerosis" Quanterix Simoa® technology was instrumental in measuring biomarkers (sNFL & sGFAP) indicative of patient response to treatment. These findings showcase how advanced biomarker analysis can elucidate and improve treatment outcomes for multiple sclerosis patients. Read more here: https://bit.ly/4gBKGo5
Quanterix
Biotechnology Research
Billerica, Massachusetts 16,935 followers
Discovery Fueled by Ultra-Sensitivity
About us
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
- Website
-
http://www.quanterix.com
External link for Quanterix
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Billerica, Massachusetts
- Type
- Public Company
- Founded
- 2007
- Specialties
- ultrasensitive immunoassay, digital ELISA, proteomics, biomarkers, assays, neurology, oncology, and diagnostics
Locations
-
Primary
Get directions
900 Middlesex Tpke
Billerica, Massachusetts 01821, US
Employees at Quanterix
Updates
-
Last night, we celebrated an incredible year at our company holiday party, filled with laughter, connection, and plenty of festive fun! 🎁✨ To our amazing Quanterix team: Thank you for your dedication, hard work, and passion. You’re the heart of everything we achieve, and we couldn’t do it without you. Here’s to a joyful holiday season and an even brighter year ahead. #EmployeeAppreciation #Quanterix
-
-
Enabling ultra-sensitive measurement of IL-17A, IL-4, IL-13, and IL-5 at femtogram levels, the Simoa® Cytokine 4-Plex B Advantage PLUS Assay provides valuable insights into inflammation associated with infections, allergens, #cancers, and more. Learn more about the applications of C4PB ➡️ https://bit.ly/4gt0yt4
-
-
Gain insights from Dr. Laia Montoliu Gaya, a pioneer in blood-based tau detection for Alzheimer’s diagnosis, on how biomarkers and blood-based diagnostics are breaking barriers in early detection, enabling broader access to accurate Alzheimer’s disease diagnosis across diverse populations. View the on-demand webinar: https://bit.ly/4ikaHtA
-
-
Such a great conversation with Dr. Henrik Zetterberg and Mark T. Roskey, Ph.D. on the power of ultra-sensitive biomarkers for Alzheimer’s disease. We’ve collaborated with pioneers like Dr. Zetterberg and many others for more than a decade and we know the future is bright for Alzheimer’s discovery, diagnostics and care.
Here is a quick exclusive look at my fireside chat with Dr. Henrik Zetterberg, a leading neurology researcher and global thought leader in Alzheimer’s disease research. Henrik and I discussed his invaluable insights on the latest advancements and trends in the use of blood-based biomarkers that are shaping the future of Alzheimer’s diagnostics and care. This highlight reel is just the beginning—don’t miss the full recording for the complete conversation! 👉 Watch now: https://lnkd.in/eYzHkkNp #CTAD2024 #AlzheimersResearch #Innovation #ExpertInsights
Highlight: Fireside Chat with Dr. Henrik Zetterberg | CTAD 2024
https://www.youtube.com/
-
Meet Danilo, one of our Field Application Scientists. Our team provides expert training on instrument operation—from setup to final analysis—and hands-on assay experience. Need training for new staff or a refresher? We're booking meetings for Q1 now: https://bit.ly/41jNzFq
-
-
#throwbackthursday CTAD 2024 fueled momentum in advancing Alzheimer's detection with a focus on blood based biomarkers. Review highlights from University of California at San Francisco (UCSF) and Seoul National University Hospital in our blog post here ➡️ https://bit.ly/4eYn4IX #CTAD2024 #alzheimers #biomarkers
-
-
Able to simultaneously measure NfL, GFAP, UCH-L1, and BD-Tau in both blood and cerebrospinal fluid CSF, the Simoa® N4PD Advantage PLUS assay offers streamlined workflows and robust brain-specific insights. Download the flyer to learn more ➡ https://bit.ly/4fT78ZR #Neurology #BloodBiomarker #ClinicalResearch
-
-
Discover how the Cytokine 4-Plex A Assay is uncovering critical insights into early biological and pathological processes, advancing our understanding of inflammation and immune function. Explore the applications of C4PA➡️ https://bit.ly/3ZxJ74F #Immunology #Inflammation #Cytokines
-
-
Coming up! Dec. 5 we will be sharing the remarkable breakthroughs of Simoa® users at our upcoming Simoa Success Seminar. Join us in exploring how Simoa technology is advancing research in neurological #biomarkers, brain-derived extracellular vesicles, and more. Register: https://bit.ly/40EHpzB
-